RT Journal Article
T1 A comprehensive review on novel targeted therapy methods and nanotechnology-based gene delivery systems in melanoma.
A1 Rahimi, Azadeh
A1 Esmaeili, Yasaman
A1 Dana, Nasim
A1 Dabiri, Arezou
A1 Rahimmanesh, Ilnaz
A1 Jandaghain, Setareh
A1 Vaseghi, Golnaz
A1 Shariati, Laleh
A1 Zarrabi, Ali
A1 Javanmard, Shaghayegh Haghjooy
A1 Cordani, Marco
AB Melanoma, a malignant form of skin cancer, has been swiftly increasing in recent years. Although there have been significant advancements in clinical treatment underlying a well-understanding of melanoma-susceptible genes and the molecular basis of melanoma pathogenesis, the permanency of response to therapy is frequently constrained by the emergence of acquired resistance and systemic toxicity. Conventional therapies, including surgical resection, chemotherapy, radiotherapy, and immunotherapy, have already been used to treat melanoma and are dependent on the cancer stage. Nevertheless, ineffective side effects and the heterogeneity of tumors pose major obstacles to the therapeutic treatment of malignant melanoma through such strategies. In light of this, advanced therapies including nucleic acid therapies (ncRNA, aptamers), suicide gene therapies, and gene therapy using tumor suppressor genes, have lately gained immense attention in the field of cancer treatment. Furthermore, nanomedicine and targeted therapy based on gene editing tools have been applied to the treatment of melanoma as potential cancer treatment approaches nowadays. Indeed, nanovectors enable delivery of the therapeutic agents into the tumor sites by passive or active targeting, improving therapeutic efficiency and minimizing adverse effects. Accordingly, in this review, we summarized the recent findings related to novel targeted therapy methods as well as nanotechnology-based gene systems in melanoma. We also discussed current issues along with potential directions for future research, paving the way for the next-generation of melanoma treatments.
PB ELSEVIER
SN 1879-0720
YR 2023
FD 2023-05-24
LK https://hdl.handle.net/20.500.14352/72418
UL https://hdl.handle.net/20.500.14352/72418
LA eng
NO European UnionNextGeneration (EU/PRTR)
NO Ministerio de Ciencia e Innovación (MICINN)/Agencia Estatal de Investigación (AEI)
NO Ministerio de Universidades
NO Universidad Complutense de Madrid (UCM)
DS Docta Complutense
RD 21 mar 2026